Seroxat, which is manufactured by GlaxoSmithKline, is one of the most commonly prescribed antidepressants. But some who have taken it have claimed they became hooked on the drug, while others have ...

A re-analysis of a clinical trial of GlaxoSmithKline's antidepressant Seroxat suggests the drug is ineffective and unsafe in younger patients, contradicting its earlier conclusions. The new study ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Your account has not been activated. Please check and click the activation email, or click here to resend Your login and/or password information does not match our ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

Here’s a bitter pill for GSK to swallow this morning. The OFT has released a ‘Statement of Objections’ alleging that the pharmaceutical giant paid rivals to delay the release a treatment for ...

GSK’s twice-yearly depemokimab reduced asthma attacks by half and cut clinic visits by nearly three-quarters, positioning it ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

In 2021, GSK said the factory was likely to close in 2025 when its contract with Sandoz ceased "in the absence of any other ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...